The Peptide Perspective: Decoding the Rising Influence of the Peptide Therapeutics Market

The ENT diagnostic devices market remains moderately consolidated among top 5 players who hold over half the market share.

Top 5 players in the ENT diagnostic devices market are Medtronic Plc, Fujifilm Corporation, Smith and Nephew Plc., Stryker Corporation and Natus Medical Incorporated.

Increasing revenues of these companies are challenging the hegemony of leading players in the ENT diagnostic devices market.As the medtech industry has shifted from marketing model to a care delivery model, greater strides are underway in the field of the medical diagnostic technology landscape.

In a bid to introduce improved diagnosis, the ENT diagnostic devices marketplace has witnessed the introduction of multiple breakthrough innovations.Telemedicine is a phenomenon in the otolaryngology which brings medical care to patients.

For instance, after Cupris Health’s introduction of smartphone otoscope in January 2018, in May 2018, hearX Group introduced the world’s first clinically validated smartphone audiometry solution hearTest.Problems associated with ear, nose and throat are among the most common factors responsible for hospital visits, particularly among the pediatric population.

Between 10 to 30% of the population in the United States and Europe is affected by Sinusitis.Advances in the accessibility of healthcare facilities and favorable reimbursement policies for ENT procedures have increased the number of ENT surgeries performed for the treatment of ENT related diseases.

Transparency Market Research (TMR) has published a new report titled, ‘Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

According to the report, the global peptide therapeutics market was valued at US$ 25.0 Bn in 2018 and is projected to expand at a CAGR of 7.9% from 2019 to 2027.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=418OverviewPeptides are the combination of two or more amino acid monomers linked by amide bonds.

As a benchmark, molecules with less than 50 amino acids are considered as peptides.

The CMOs which provide end-to-end service to the biotech pharmaceutical companies are growing due to shift in focus of pharma companies to explore better opportunities in the peptide therapeutics market.

Therapeutics peptides application in cancer treatment has opened a promising avenue for future growth of peptide therapeutics marketBesides, surge in prevalence and incidence rate of other chronic conditions such as diabetes, cardiac diseases and immune disorders, owing to increasing geriatric population is projected to propel the global peptide therapeutics market.Cancer Segment to Dominate Peptide Therapeutics MarketIn terms of application, the global peptide therapeutics market has been segmented into cancer, metabolic, CVD, respiratory, GIT, anti-infective, dermatology, CNS, and renal.

The cancer segment dominated the global peptide therapeutics market in 2018and the trend is projected to continue during the forecast period.